These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19422663)

  • 1. Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
    McCoy MJ; Nowak AK; Lake RA
    Tissue Antigens; 2009 Jul; 74(1):1-10. PubMed ID: 19422663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Environmental cancer: malignant pleural mesothelioma].
    Margery J; Ruffié P
    Bull Cancer; 2008 Jan; 95(1):77-86. PubMed ID: 18230573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
    Ampollini L; Soltermann A; Felley-Bosco E; Lardinois D; Arni S; Speck RF; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):457-62. PubMed ID: 19162494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belmont Hyperthermia Pump in the conduct of intra-operative heated chemotherapy.
    Riley W
    Perfusion; 2009 Mar; 24(2):115-8. PubMed ID: 19654155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
    Izzi V; Masuelli L; Tresoldi I; Foti C; Modesti A; Bei R
    Cancer Lett; 2012 Sep; 322(1):18-34. PubMed ID: 22394996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunological aspects of anticancer chemotherapy].
    Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
    Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SV40 and the pathogenesis of mesothelioma.
    Rizzo P; Bocchetta M; Powers A; Foddis R; Stekala E; Pass HI; Carbone M
    Semin Cancer Biol; 2001 Feb; 11(1):63-71. PubMed ID: 11243900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelioma: path to multimodality treatment.
    Su S
    Semin Thorac Cardiovasc Surg; 2009; 21(2):125-31. PubMed ID: 19822284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for mesothelioma: rationale and new approaches.
    Reuss JE; Forde PM
    Clin Adv Hematol Oncol; 2020 Sep; 18(9):562-572. PubMed ID: 33006585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy in malignant mesothelioma].
    Tokat AO; Kutlay H
    Tuberk Toraks; 2003; 51(4):456-60. PubMed ID: 15143397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of malignant pleural mesothelioma--present status and future view].
    Yano T; Morodomi Y; Ito K; Miura N; Takenaka T; Kawano D; Shoji F; Maehara Y
    Fukuoka Igaku Zasshi; 2008 Apr; 99(4):74-9. PubMed ID: 18646592
    [No Abstract]   [Full Text] [Related]  

  • 15. [Malignant mesothelioma].
    Scherpereel A
    Rev Prat; 2009 Jun; 59(6):751-5. PubMed ID: 19642427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
    Radfar S; Wang Y; Khong HT
    J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
    Friedberg JS
    Semin Thorac Cardiovasc Surg; 2009; 21(2):177-87. PubMed ID: 19822291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based immunotherapy in mesothelioma.
    Cornelissen R; Lievense LA; Heuvers ME; Maat AP; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
    Immunotherapy; 2012 Oct; 4(10):1011-22. PubMed ID: 23148753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac tamponade complicating trimodal therapy for malignant mesothelioma.
    Sawar A; Schocken DD
    Heart Lung; 2006; 35(5):355-7. PubMed ID: 16963368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.